Reuters logo
BRIEF-Abbvie's upadacitinib meets primary endpoint in phase 2b study in atopic dermatitis
September 7, 2017 / 12:16 PM / 2 months ago

BRIEF-Abbvie's upadacitinib meets primary endpoint in phase 2b study in atopic dermatitis

Sept 7 (Reuters) - Abbvie Inc

* Abbvie’s upadacitinib (abt-494) meets primary endpoint in phase 2b study in atopic dermatitis

* Abbvie Inc - “‍look forward to advancing upadacitinib to phase 3 studies in 2018”​

* Abbvie Inc - ‍upadacitinib is not approved by regulatory authorities and safety and efficacy have not been established​

* Abbvie-‍results showed that primary, secondary endpoints, patients treated with upadacitinib achieved improvements that were statistically significant

* Abbvie Inc - ‍in study, no new safety signals were detected​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below